All the fuss surrounding the proposal by India and South Africa to suspend the TRIPS Agreement to help them produce vaccines to fight COVID-19 has obscured some critical truths. In spite of the rallying cry “Patents versus People,” it’s not really about patents. And merely lifting TRIPS obligations will do nothing to address the current suffering of the world’s poorer populations. In fact, it would hamper efforts to secure global distribution of vaccines, as well as cause real harm in the long term.
Patent
- Enablement
- Fee Shifting
- Litigation
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?
- A Kinder, Gentler ‘Death Squad’: Ten Years in, Despite Some Reforms, the USPTO is Still Killing U.S. Patents
Recent Posts
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- International: WIPO Reports Increasing Prevalence of Alternative Dispute Resolution for Business-to-Business Copyright Disputes
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?